MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

ESPERION THERAPEUTICS INC

Gesloten

SectorGezondheidszorg

2.89 -0.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.8

Max

2.92

Belangrijke statistieken

By Trading Economics

Inkomsten

28M

-13M

Verkoop

17M

82M

Winstmarge

-15.446

Werknemers

304

EBITDA

37M

16M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+138.62% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

239M

534M

Vorige openingsprijs

3.23

Vorige sluitingsprijs

2.89

Nieuwssentiment

By Acuity

58%

42%

314 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

ESPERION THERAPEUTICS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 okt 2025, 23:30 UTC

Populaire aandelen

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 okt 2025, 21:21 UTC

Winsten

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 okt 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 okt 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 okt 2025, 23:39 UTC

Marktinformatie

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 okt 2025, 23:00 UTC

Marktinformatie

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Scales's JV Buyout Lauded by Bull -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Forex and Fixed Income Roundup: Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 okt 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 okt 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

2 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 okt 2025, 20:49 UTC

Acquisities, Fusies, Overnames

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 okt 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 okt 2025, 19:20 UTC

Marktinformatie

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 okt 2025, 19:10 UTC

Marktinformatie

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 okt 2025, 19:04 UTC

Marktinformatie

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 okt 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Vergelijking

Prijswijziging

ESPERION THERAPEUTICS INC Prognose

Koersdoel

By TipRanks

138.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.92 USD  138.62%

Hoogste 16 USD

Laagste 1.6 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor ESPERION THERAPEUTICS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

4

Buy

0

Hold

1

Sell

Technische score

By Trading Central

0.85 / 1.05Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

314 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
help-icon Live chat